TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03617861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Secretin
Description: Injected once over one minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Secretin
Description: Injected once over one minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Secretin
Description: Injected once over one minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Secretin
Description: Injected once over one minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injected once over one minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injected once over one minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injected once over one minute
Study: NCT03716947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: ZACK
Description: Surgical procedure with total disc replacement using ZACK disc prostheses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: ZACK
Description: Surgical procedure with total disc replacement using ZACK disc prostheses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: ORBIT
Description: Surgical procedure with total disc replacement using ORBIT disc prostheses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: ORBIT
Description: Surgical procedure with total disc replacement using ORBIT disc prostheses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: SASCA
Description: Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: SASCA
Description: Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
Study: NCT02396758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekosonic® Endovascular Device ultrasonic infusion catheter
Description: r-tPA will be administered via EKOS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekosonic® Endovascular Device ultrasonic infusion catheter
Description: r-tPA will be administered via EKOS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekosonic® Endovascular Device ultrasonic infusion catheter
Description: r-tPA will be administered via EKOS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekosonic® Endovascular Device ultrasonic infusion catheter
Description: r-tPA will be administered via EKOS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Description: Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Description: Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Description: Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Description: Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
Study: NCT03220776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo
Study: NCT01780545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles.
Study: NCT02814097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Study: NCT00498433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5 mg capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Aliskiren
Description: Matching placebo of aliskiren 300 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Aliskiren
Description: Matching placebo of aliskiren 300 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of amlodipine
Description: Matching placebo of amlodipine 5 mg capsule
Study: NCT04672499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 300 mg tablets
Description: Miricorilant 300 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 150 mg tablets
Description: Miricorilant 150 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 150 mg tablets
Description: Miricorilant 150 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 150 mg tablets
Description: Miricorilant 150 mg tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 150 mg tablets
Description: Placebo to match miricorilant 150 mg tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 150 mg tablets
Description: Placebo to match miricorilant 150 mg tablets for oral administration
Study: NCT02812628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPR
Description: Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAPR-TILT
Description: Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
Study: NCT00700947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (TOPROL-XL® )
Description: Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
Study: NCT02324309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix 75/25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin R U-500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531
Study: NCT02536547

Intervention type: DEVICE
Intervention: VAP
Description: all patients with suspected VAP : biochemestry microbiology lung ultrasound
Study: NCT04838145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin + Pleconaril
Description: Randomized to treatment with study drugs (ribavirin and pleconaril)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Randomized to treatment with placebo
Study: NCT04199676

Intervention type: DIAGNOSTIC_TEST
Intervention: Glucose tolerance test
Description: Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
Study: NCT03739190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NRL Condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NRL Condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NRL Condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
Study: NCT01165502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: MAD study with repeated subcutaneous (sc) doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for compound CM3.1-AC100 s.c.
Study: NCT03342170

Intervention type: GENETIC
Intervention: G20210A prothrombin gene mutation and Factor 5 Leiden mutation
Description: blood sample

Intervention type: GENETIC
Intervention: G20210A prothrombin gene mutation and Factor 5 Leiden mutation
Description: blood sample
Study: NCT02445183

Intervention type: OTHER
Intervention: None, N/A

Intervention type: OTHER
Intervention: None, N/A
Study: NCT01394783

Intervention type: DEVICE
Group type: OTHER
Intervention: Miller laryngoscope
Description: Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.

Intervention type: DEVICE
Group type: OTHER
Intervention: Storz videolaryngoscope
Description: Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
Study: NCT04665778

Intervention type: OTHER
Intervention: hospital bedroom booking
Description: Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
Study: NCT03962478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent and high-intensity focused ultrasound ablation system
Description: Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: Self-expandable biliary nitinol alloys stent
Study: NCT03552237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fiber
Description: We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
Study: NCT00937456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopically-assisted esophagectomy
Description: To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopically-assisted esophagectomy
Description: To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
Study: NCT04265911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772 (subcutaneous)
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772 (subcutaneous)
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772 (intramuscular)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772 (intramuscular)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23 (subcutaneous)
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23 (intramuscular)
Description: Intramuscular injection
Study: NCT03116672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one dose ketorolac 10 mg
Description: Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One dose Diclofenac
Description: Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Administration of Placebo, 15 minutes before the clinical procedure.
Study: NCT03617861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injected once over one minute
Study: NCT01877551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tauroursodeoxycholic acid
Description: The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
Study: NCT04600063

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Isolation procedure (RAMPS procedure)
Description: In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
Study: NCT03248713

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone 600mg 2 tablets will be compared to the placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo sugar 2 tablets will be compared to mifepristone
Study: NCT00553605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen 100mg
Description: Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib 40mg
Description: Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
Study: NCT02358213

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound examinations are done 5 times
Study: NCT04299113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Given PO
Study: NCT02017132

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate extract
Study: NCT04664985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucogyne® ovule
Description: hyaluronic acid, vaginal ovule
Study: NCT01885936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
Study: NCT04563247

Intervention type: DIAGNOSTIC_TEST
Intervention: IgG SARS CoV 2 antibodies
Description: The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
Study: NCT04157959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1
Description: Tablet,dose1,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1
Description: Tablet,dose1,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat dose2
Description: Tablet,dose2,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat dose2
Description: Tablet,dose2,QD
Study: NCT00797511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TdcP-IPV vaccine
Description: 0.5 mL, Intramuscular
Study: NCT00001077

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamin and mineral supplements
Description: Oral tablets taken daily

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamin and mineral supplements
Description: Oral tablets taken daily

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamin and mineral supplements
Description: Oral tablets taken daily

Intervention type: DIETARY_SUPPLEMENT
Intervention: Peptamen
Description: Solution received daily

Intervention type: DIETARY_SUPPLEMENT
Intervention: NuBasics
Description: Solution or dietary bar received daily
Study: NCT04503837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Mobile Phone Video Recording
Description: Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
Study: NCT03461211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).